Larazotide

Summary

Larazotide (CHEMBL2105646) is a phase-3 clinical-stage protein; indicated across 1 condition including celiac disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 725.8 Da · C32H55N9O10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105646
Name	Larazotide
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	9810532
Molecular formula	C32H55N9O10
Molecular weight	725.8
InChIKey	ORFLZNAGUTZRLQ-ZMBVWFSWSA-N

SMILES: CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN

IUPAC name: 2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid

Also known as: AT-2347, Larazotida, Larazotide, LARAZOTIDE

Parent form; salt/anhydrous children: CHEMBL2103815

Patent coverage: 53 distinct patent families (134 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
celiac disease	3	MONDO:0005130	EFO:0001060

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03569007	PHASE3	TERMINATED	Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).